Table 2.
Immunization protocol.
| Groups | Pig ID | Dose per construct | Total dose per pig | Adjuvant |
|---|---|---|---|---|
| CS* Group 1 | 6908 | none | ||
| 6886 | ||||
| Luc-ISA-201 | 6894 | 4.2 × 1011 ifu | 4.2 × 1011 ifu | Montanide ISA-201™ |
| 6909 | ||||
| 6896 | ||||
| 6897 | ||||
| 6888 | ||||
| CS* Group 2 | 6915 | None | ||
| 6901 | ||||
| ASFV-No adjuvant | 6898 | 1 × 1010 ifu | 4.2 × 1011 ifu | No adjuvant |
| 6903 | ||||
| 6893 | ||||
| 6892 | ||||
| 6900 | ||||
| CS* Group 3 | 6887 | none | ||
| 6906 | ||||
| ASFV-ISA-201 | 6884 | 1 × 1010 ifu | 4.2 × 1011 ifu | Montanide ISA-201™ |
| 6885 | ||||
| 6883 | ||||
| 6902 | ||||
| 6910 | ||||
| CS* group 4 | 6912 | none | ||
| 6907 | ||||
| ASFV-BioMize | 6913 | 1 × 1010 ifu | 4.2 × 1011 ifu | BioMize® |
| 6891 | ||||
| 6890 | ||||
| 6899 | ||||
| 6904 | ||||
*CS, Contact spreaders. No inoculum or adjuvant received and direct intramuscular challenge.